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Abstract. Persistent systemic hypoxia, a direct consequence of alterations in vascular function, can compromise the brain by
increasing the risk of developing dementias such as Alzheimer’s disease (AD). Vascular contributions to cognitive impairment
and AD in aged individuals are common, and several vascular risk factors for AD are linked to hypoxia. Clinical evidence
confirms that structural and functional changes characteristic of AD pathology also occur following hypoxic-ischemic events
such as stroke and traumatic brain injury. Studies with transgenic and non-transgenic mouse models reliably show that hypoxia
increases the levels of amyloid- peptides that form the characteristic plaques in AD brains. Moreover, some studies suggest that
vascular lesions also promote tau phosphorylation, modulate apolipoprotein E expression, and have more profound in effects in
aged animals, but additional evidence is needed to establish these findings. Although the mechanisms underlying hypoxia-related
effects remain unclear, controlled animal studies continue to reveal mechanistic aspects of the relationship between hypoxia and
AD pathology that are necessary for therapeutic developments. The present review summarizes evidence from rodent studies
regarding the effects of hypoxia on AD-related pathology and evaluates its impact on understanding human disease.
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INTRODUCTION21
Alzheimer’s disease (AD) is one of the most preva-22
lent neurodegenerative diseases associated with aging.23
The majority of AD cases manifest as a late onset spo-24
radic form, accounting for more than 95% of cases,25
but genetically the disease is divided into familial26
and sporadic cases [1]. Familial AD is caused by27
mutations in the amyloid- protein precursor (APP)28
and presenilin 1 and 2 genes [2]. Risk factors for29
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sporadic AD include age, ApoE ε4 polymorphism, 30
hypercholesterolemia, hypertension, diabetes melli- 31
tus, stroke, brain trauma, and obesity, among others 32
[1]. The two main pathological hallmarks of AD are 33
accumulation of amyloid- (A) plaques in brain tis- 34
sue and in the walls of the small brain arteries and 35
hyperphosphorylated tau filaments that aggregate as 36
neurofibrillary tangles (NFTs). A plaques and NFTs 37
lead to cell and synaptic dysfunction and ultimately 38
result in cognitive and functional deterioration. AD 39
is frequently accompanied by vascular pathology, and 40
various mouse models of AD have been employed in 41
investigations of how alterations in vascular function 42
impact AD-related processes, primarily those related 43
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to the expression of A. According to the amyloid44
hypothesis, formation of A plaques is one of the main45
influences on AD pathogenesis, and disease processes46
are believed to result from an imbalance between47
A production and clearance [3]. Hypoxia, a direct48
consequence of cerebral hypoperfusion, increases A49
production and reduces its clearance [4], and may50
trigger mechanisms that contribute to the cognitive51
impairment in AD patients. Moreover, hypoxia also52
induces microglia activation which results in the pro-53
duction of inflammatory cytokines and subsequent54
structural damage and neuroinflammation [5–7].55
Currently, the proposed classification criteria for AD56
consist of core clinical features with evidence of patho-57
physiological processes, which include biomarkers of58
brain A protein and downstream neuronal degenera-59
tion or injury [8]. Moreover, the term mild cognitive60
impairment has been coined to denote the early stages61
of cognitive decline that precede AD dementia [9].62
The clinical features of vascular dementia, which are63
attributed to vascular-related brain lesions, are more64
variable than in AD dementia with respect to neuropsy-65
chological profiles, clinical phenotypes, and disease66
onset [10]. The diagnosis of vascular dementia is com-67
plicated further by the use of various clinical criteria68
[10–12]. Additionally, a wide range of vascular lesions69
produce cognitive impairment in vascular dementia70
[10]; thus, cognitive decline is not reliably associated71
with vascular pathology nor are there consensus crite-72
ria for pathological features of vascular dementia.73
Vascular contributions to cognitive impairment and74
AD in aged individuals are common, and several vascu-75
lar risk factors for AD are linked to hypoxia. Vascular76
pathology coexists in at least one-third of AD cases77
[13, 14], and a growing body of clinical-pathological78
research suggests that vascular factors play a role in the79
pathogenesis of AD [15]. Studies with transgenic and80
non-transgenic rodents provide supporting evidence81
that hypoxia promotes A accumulation by enhancing82
A production and reducing its clearance. Moreover,83
some studies suggest that vascular lesions also pro-84
mote tau phosphorylation, but additional evidence is85
needed to establish this link. Currently the use of ani-86
mal models to investigate the factors linking cerebral87
blood flow and AD pathology is the best approach for88
uncovering the mechanisms underlying the impact of89
neurovascular alterations on AD. In the present review,90
we summarize evidence from transgenic (Table 1)91
and non-transgenic (Table 2) rodent studies regard-92
ing the effects of hypoxia on AD-related pathology93
and evaluate its impact on understanding human94
disease.95
CLINICAL-PATHOLOGICAL LINKS 96
BETWEEN AD AND HYPOXIA 97
With aging, the human body becomes less efficient 98
at delivering oxygen to cells and tissues, and therefore 99
entire organs are compromised. The brain is particu- 100
larly susceptible to hypoxia which can result in varying 101
degrees of neural failure and structural damage [16]. 102
Several cardiovascular and respiratory disorders are 103
associated with neurodegenerative pathologies includ- 104
ing AD, Parkinson’s disease, and Huntington’s disease 105
[17]. The link between hypoxia and neurodegeneration 106
is based on the oxygen supplies that are required for 107
proper nervous system function. The brain consumes 108
about 20% of the body’s oxygen and receives up to 109
20% of the cardiac output [17, 18]. Under normal con- 110
ditions oxygen is transported to brain tissue through 111
microvessels by diffusion, and rapid localized delivery 112
of oxygen occurs in response to increases in neuronal 113
activity [19]. Imaging studies suggest that oxygen lev- 114
els vary widely among different regions of the brain 115
even in the resting state [18]. Further, although is it 116
not clear whether cerebral hypoperfusion is a cause 117
or a consequence of AD, various neuroimaging stud- 118
ies in AD individuals confirm a reduction in cerebral 119
blood flow (CBF) from early to late stages of AD pro- 120
gression [20]. Vascular risk factors for hypoperfusion 121
such as ischemic stroke, atherosclerosis, hypertension, 122
diabetes and cardiac disease can lead to cognitive 123
impairment by triggering hemodynamic changes in the 124
brain microcirculature and impairing optimal delivery 125
of oxygen and glucose to the brain [21]. Hypoperfusion 126
also contributes to arterial stenosis by reducing CBF, 127
preventing microemboli from being washed out of the 128
arteries and restricting the transport of key nutrients 129
[21]. 130
The obstruction of blood resources to regions of the 131
brain such as that which occurs following stroke rep- 132
resents one of the most damaging forms of hypoxia 133
and can lead to severe pathological consequences [17]. 134
Neuroimaging studies with positron emission tomog- 135
raphy (PET) and single photon emission computerized 136
tomography (SPECT) provide evidence that stroke 137
produces region-specific hypoperfusion that results in 138
the brain receiving just enough blood supply to support 139
tissue viability but not enough to support cognitive or 140
neurological function [22, 23]. In addition, the acute 141
pathogenesis of stroke involves the activation of pro- 142
inflammatory mediators that may exacerbate tissue 143
damage in the long term [24, 25]. Various studies have 144
confirmed that stroke victims are significantly more 145
likely to develop AD in the years following stroke [26]. 146
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Table 1
Studies employing AD transgenic mouse models to examine links between low oxygen brain levels and AD pathology
Model Characteristics (age, gender, strain)1 Treatment/Approach Effects on AD-related pathology [ref]
Triple-transgenic mice (3xTg-AD) 15 months, male Temporal occlusion of the bilateral common
carotid arteries (12 min)
Decreased total tau and AT270; increased pAKT and
GSK3 three months after injury [60].
3 months, male Temporal occlusion of the bilateral common
carotid arteries (4 min)
Elevated A42 and oligemia for >3 weeks; robust
increase in BACE1; reduced tau [58].
5–7 months, both genders, homozygous Experimental TBI with cortical impact by an
electromagnetic device to produce mild,
mild-moderate, and moderate injuries
Intra-axonal A accumulation in the pericontusional
fimbria; increased tau immunoreactivity in regions
with moderate injury; increased total tau in
contralateral CA1 [105].
Transgenic ArcA mice 4 and 24 months, both genders, expressing
human APP 695 with both Swedish and
Arctic mutation
CE-MRA was used to assess cerebral
artery and vein diameters
Reduction of functional intracortical microvessels;
accumulation of A and fibrinogen in small and
medium sized vessels but not in large arteries in
24-month-old mice [68].
Transgenic mice (ApoE, APPsw
and Tg2576)
15 months, APPsw mice expressing
endogenous murine ApoE and APPsw,
mice expressing human ApoE ε3 and
ApoE ε4 isoforms (knock-in mice
Tg2576)
Development of amyloid plaques and CAA No A deposition at 15 months after CAA with
parenchyma plaque depositions in APPsw mice
expressing ApoE ε4 and ApoE ε3; elevated levels of
A1-40 and A1-42 and increased A40 : 42 ratios in
young animals expressing ApoE ε4 [71].
3–4 and 16–17 months, male, homozygous
targeted replacement mice expressing
human ApoE ε3 (TRE3) and ApoE ε4
(TRE4) genes
Intracerebral injections of human A1-40 Increased A deposits in hippocampus in TRE4 relative
to TRE3 in both 3- and 6-month-olds [88].
Transgenic mouse models using
APP and BACE genes
25–26 months, female heterozygous
APP51/16 mice, female heterozygous
APP23 mice, male heterozygous
APP23
CAA association with alterations in
microvascularisation
Severe CAA in thalamic vessels in APP23 mice
compared to APP51/16 and wt; CAA-related
capillary occlusion within the thalamus in APP23
but not in APP51/16 or wt mice [70].
Two modified animal strains, APP −/− and
BACE −/−
Global cerebral ischemia performed by
bilateral clamping of the common carotid
arteries (12 min)
APP −/− and BACE −/− mice presented greater risk
of mortality and reduced CBF under hypoxic
conditions; serum response factor and calsequestrin
significantly altered in both strains [61].
6, 11, and 20 months, male APP23
transgenic mice
Magnetic resonance angiography used to
evidence cerebral arterial hemodynamics
APP23 mice of 11 and 20 months presented flow voids
in the internal carotid arteries, with vessel elimination
and deformation [67].
2 months, mice overexpressing a mutant
form of human APP, Swedish and
Indiana (APPsw/ind-Tg mice)
Chronic cerebral hypoperfusion with BCAS
using microcoils
Impaired learning in BCAS-operated APPsw/ind-Tg
mice; reduced neural density correlated with low
cognitive performance [65].
Aged APPsw/0 mice overexpressing human
APP
Inhibition A1-40 and A1-42 with RAGE
specific blocker, FPS-ZM1, and induced
cellular stress
FPS-ZM1 inhibited RAGE mediated influx of
circulating A1-40 and A1-42; inhibited -secretase
activity and A production; blocked RAGE activity at
the BBB [50].
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Table 1
(Continued)
Model Characteristics (age, gender, strain)1 Treatment/Approach Effects on AD-related pathology [ref]
8 months, female, APP23 transgenic mice Hypoxia produced in chamber at 8% O2 for
16 h/day for 1 month
Upregulation of BACE1 promoter activity; increased
APP processing and A generation, -secretase
cleavage of APP and A deposition; impaired
memory [64].
6 months, APP/PS1 double transgenic mice Hypoxia produced by enclosure in airtight jar Decreased memory and cognitive function; increased
senile plaques and levels of tau phosphorylation [62].
10 weeks, males APP/PS1 double
transgenic mice
Hyperoxia produced in normobaric chamber
at 40% O2 for 8 h/day
Reversed deficits in spatial learning and memory;
decreased A deposition and neuritic plaque
formation in cortex and hippocampus [66].
Transgenic CD-1 mice 6–8 weeks Treatment with 3 intraperitoneal injections
of LPS from Salmonella typhimuriem
Inhibitions of CSF bulk flow, impairment of central and
peripheral clearance of A, and increased vascular
sequestration of A [82].
Transgenic PDAPP mice 4 months, mice containing the familial AD
mutation V→ F at APP position 717
(PDAPP)
Brain trauma induced by impacting a 3-mm
diameter impounder onto the cortex
through a 5-mm craniectomy
Increased A, increased hippocampal neuronal death
and memory impairment, but no increase in A
plaque formation [104].
Transgenic APP-YAC mice Both genders, heterozygous Brain injury by controlled cortical impact Significant motor and memory deficits in WT and
APP-YAC mice 7 days post brain injury [103].
AD, Alzheimer’s disease; ApoE ε3, apolipoprotein E ε3; ApoE ε4, apolipoprotein E ε4; APP, amyloid- protein precursor; APPsw/ind-Tg mice, transgenic mice with APP and two mutations,
Swedish and Indiana; APP 695, amyloid- protein precursor 695; AT270, tau phosphorylated at Thr181; BACE1, beta-site amyloid- protein precursor cleaving enzyme 1; BCAS, bilateral
common carotid artery stenosis; CAA, cerebral amyloid angiopathy; CBF, cerebral blood flow; CE-MRA, contrast-enhanced magnetic resonance microangiography; CSF, cerebrospinal fluid;
C99, membrane-bound peptide generated from APP; F, phenylalanine; FPS-ZM1, High affinity RAGE specific inhibitor; GSK3, glycogen synthase kinase 3 beta; LPS, lipopolysaccharides;
pAKT, serine/threonine-specific protein kinase; PS1, Presenilin 1; RAGE, receptor for advanced glycation end products; TBI, traumatic brain injury; wt, wildtype; V, valine; YAC, yeast artificial
chromosome; 3xTg-AD, Triple-transgenic mice for AD. 1Information provided when available.
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Table 2
Studies employing non-transgenic animals to examine links between low oxygen brain levels and AD pathology
Animal model Characteristics (age, gender)1 Treatment/Approach Effects on AD-related pathology [ref]
Mongolian gerbils Male BCO, 10 min to produce global ischemia Loss of 90% of the CA neurons 24 to 72 h after ischemia; decreased APP
and A immunostaining at 24 h after ischemia; increased APP and A
after 48 h that overlapped with increased ApoE expression and glial
fibrillary acidic protein [80].
Sprague-Dawley rats 3–20 months, male Reversible occlusion of the cerebral middle
artery to produce focal cerebral ischemia
Upregulation of APP and A fragments; presence of APP and A in
large round cells between macrophages from blood and/or brain in the
infarct region (core and penumbra). Focal accumulation of APP and
A in adult rats [73].
23 weeks, male 2VO Deficits in memory after 30 days that worsened after 180 days in aged but
not young adult rats; decreased cytochrome oxidase activity mostly in
hippocampus and accumulation of A oligomers in the CA1 area after
180 days 2VO [77].
Wistar rats Male 4 groups: bilateral A
intracerebroventricular injection, BCCAo,
sham, and A toxicity and BCCAo
Impaired spatial memory in A toxicity-BCCAo group compared to A
toxicity and BCCAo groups alone; exacerbated AD pathology in A
toxicity-BCCAo group compared to A toxicity group [72].
10 months, male ME, occlusion of both external carotid
arteries temporarily and then released 500
non-radioactive microspheres into the left
common carotid artery
Brain injury associated with A accumulation and tau pathology by
microvessel injury; promoted neuropathology similar to NFTs and
aberrant eNOS expression and protein tyrosine nitration in microvascular
endothelial cells consistent with A-amyloid accumulation [74].
6–9 months, male 2VO to produce progressive neuronal
damage and cholinergic dysfunction
Histologically observed infarction in the cortex of 28.6% and 42.9% in the
striatum; neural loss 4 months after 2VO in CA1 hippocampus;
rarefaction of white matter found 4 months after 2VO [78].
10 months, male 2VO Impaired learning and memory; downregulated synaptophysin in
hippocampus; downregulated MAP-2 expression; upregulated GAP-43
mRNA [76].
11 months, male tMCAO Maximal increase of ApoE expression in the core 7 days after tMCAO
detection and in periischemic region at 7 and 21 days; increased ApoE
mRNA in glial cells but not in neurons in periischemic region [89].
ApoE, apolipoprotein ε; APP, amyloid- protein precursor; AVF, arteriovenous fistula; BCCAo: permanent occlusion of bilateral common carotid arteries; BCO, bilateral carotid occlusion; CBF,
cerebral blood flow; GAP-43, growth associated protein 43; MAP-2, microtubule associated protein 2; ME, microsphere embolism; mRNA, messenger ribonucleic acid; NFTs, neurofibrillary
tangles; NO, nitric oxide; tMCAO, transient middle cerebral artery occlusion; 2VO, Permanent occlusion of bilateral common carotid arteries. 1Information provided when available.
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In addition to stroke, a reduction in the levels of oxygen147
that reach the brain is often a consequence of microin-148
farcts. A recent study of postmortem brains showed149
that chronic microinfarcts and particularly multiple150
microinfarcts elevated the likelihood of dementia [27].151
Microinfarcts located in cortical regions of the brain152
were associated with greater risk for dementia than153
those in subcortical regions [27]. Moreover, subjects154
with multiple microinfarcts exhibit greater overall cog-155
nitive impairment [27]. Clinical-pathological evidence156
shows that individuals with AD neuropathology and157
white matter or basal ganglia infarcts have a 20-fold158
increased risk of developing dementia compared to AD159
individuals without infarcts [28, 29].160
In studies with AD patients, clinical evidence shows161
that hypoxia increases the levels of APP and A in162
the vasculature of the brain [17]. Cardiac arrest, an163
extreme form of hypoxia, causes a massive increase in164
A in blood [30]. Experimental studies support clin-165
ical observations showing that ischemia promotes the166
upregulation of APP resulting in an increase in A167
accumulation and ultimately in the production of A168
plaques [31–33]. Increases in A are believed to pro-169
duce neurotoxicity by causing perturbations in Ca2+170
homeostasis, which can lead to a number of dysfunc-171
tions in cellular processes including neurotransmitter172
release and gene expression [34]. Chronic hypoxia173
has been shown to potentiate whole cell voltage-gated174
Ca2+ flows and produce overexpression of A in vari-175
ous cell types [17]. There is a growing body of evidence176
that disturbances in calcium homeostasis provide a177
mechanistic link between hypoxia and AD pathology,178
although it remains to be established how calcium alter-179
ations account for AD pathogenesis [35].180
Risk factors for cardiovascular disease have pro-181
vided further insight into the relationship between182
hypoxia and AD pathogenesis. Hypertension is a risk183
factor for AD, and there are several reports that blood184
pressure increases in patients with AD years before185
the onset of the disease [36]. Chronic hypertension is186
often accompanied by additional vascular abnormali-187
ties that may threaten an optimal blood supply to the188
brain and increase the risk for dementia [36]. However,189
because hypertension is also associated with various190
risk factors for AD, including hypercholesterolemia,191
atherosclerosis, and obesity [37], a causal link between192
hypertension and AD pathology has not been estab-193
lished. Exploration of vascular risk factors in patients194
with AD is compulsory, and ongoing prospective195
studies should offer further evidence for developing196
preventive and therapeutic treatments. Even in the pro-197
cess of normal aging there are marked changes in the198
vascular system that are associated with changes in 199
cognitive function [38]. Vascular structure and func- 200
tion are affected adversely over the course of aging by 201
stiffening of the arteries and luminal dilatation [39]. 202
An early study [40] showed that there are important 203
substances in the microvasculature that play a major 204
role in the interactions between the blood-brain barrier 205
(BBB), astrocytes, and neurons (Fig. 1). Accordingly, 206
structural changes related to microvascular pathology 207
have been shown to be greater in demented compared 208
to non-demented elderly subjects [40]. Thus, live eval- 209
uations of microvascular pathology offer a promising 210
approach to the development of useful biomarkers for 211
early detection and characterization of AD pathology 212
[41]. Together, clinical-pathological evidence brings 213
up several fundamental questions, namely, whether 214
vascular risk factors are causally related to the devel- 215
opment of dementia, and if so, whether early diagnosis 216
and treatment of these pathologies could delay or pre- 217
vent the progression of dementia. Currently, the best 218
approach to these questions is by direct manipulations 219
of oxygen supply and subsequent evaluations of behav- 220
ioral and neuropathological hallmarks of AD using 221
animal models. 222
MOLECULAR SIGNALING PATHWAYS 223
LINKING AD AND HYPOXIA 224
The molecular signaling pathways related to the 225
two main forms of neuropathology of AD, accumu- 226
lation of A and NFTs, have been characterized in 227
numerous studies and will only be briefly discussed. 228
Readers are referred to recent reviews [2, 42]. The A 229
peptide is released in brain by proteolytic processing 230
of APP. Several insults such as hypoxia (Fig. 1A) 231
can promote elevation of A peptides, and genetic 232
and environmental factors are believed to contribute 233
to a chronic imbalance between A production and 234
clearance in AD. The A peptide is the principal ele- 235
ment in the extracellular plaques seen in AD brains, 236
and insoluble forms of the peptide are produced via 237
sequential cleavage of APP by two proteases, first by 238
-site APP cleavage enzyme 1 (BACE1) followed by 239
-secretase and production of A peptides. Hypoxia 240
activates transcription factor hypoxia-inducible factor 241
1 (HIF-1), which binds to and upregulates BACE1 242
(Fig. 1A), also promoting A peptide production [43]. 243
Toll-like receptor 4 (TLR4), a pattern recognition 244
receptor mainly expressed in immune cells, is asso- 245
ciated with hypoxic episodes in tissues like brain, 246
heart, kidney, and lung [7, 44]. TLR4 is found to 247
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Fig. 1. A) Blood-brain barrier (BBB) breakdown caused by pericyte detachment leads to an accumulation of neurotoxic substances in the
brain as well as a reduction in oxygen supply. This activates hypoxia-inducible factor (HIF-1), which binds to and upregulates  amyloid
cleaving enzyme-1 (BACE). HIF-1 promotes the expression of toll like receptor-4 (TLR4) and subsequent microglia activation with release
of cytokines that upregulates BACE. Sequential cleavage of the amyloid- protein precursor (APP) by BACE and y-secretase results in the
amyloid- (A) peptide [44, 69]. Accumulation of A results in the polymerization of A into plaques that are one of the hallmarks of AD.
The plaques may be degraded by microglia or accumulate in the brain parenchyma and walls of small brain arteries leading to a reduction of
blood flow [69, 109, 110]. B) Cerebral amyloid angiopathy (CAA) also results from the accumulation of A, which leads to capillary occlusion
in the brain and a reduction of blood flow as well as local loss of neurons, microglial activation and microhemorrhage [69]. C) A plaques
may lead to hyperphosphorylation of tau protein, which contributes to neurofibrillary tangles and an increase in basement membrane thickness
surrounding cortical microvessels [62]. D) A is transported between the brain and blood through two main receptors: the receptor for advanced
glycation end products (RAGE) and the low-density lipoprotein receptor-related protein 1 (LRP-1) [50]. RAGE, located on the luminal side of
the endothelium mediates the influx of A into the brain. LRP-1, located on the abluminal endothelial cell membrane mediates efflux of free
A from the brain interstitial fluid into the blood. Soluble LRP (sLRP) is formed in the liver by cleavage of LRP through -secretase [87]. It
binds to A and is then removed by the liver and kidney. In this way, soluble LRP functions as a peripheral sink for A [111]. LRP-1 also binds
directly to APP affecting endoproteolytic processing of APP and increasing production of A [87]. Small lipophilic agents as well as O2 and
CO2 pass through the BBB by simple diffusion whereas ions require ATP-dependent transporters such as (NA+ and K+) ATPase [112].
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be overexpressed in macrophages and microglia via248
HIF-1 under hypoxia, mediating brain inflammation249
and hypoxic-ischemic-related diseases [5, 44]. Acti-250
vated microglial cells release several inflammatory251
mediators such as cytokines, reactive oxygen species,252
complement components, and nitric oxide that pro-253
mote upregulation of BACE1 (Fig. 1A) and ultimately254
increase A peptide production [7, 44, 45].255
The brain uses several routes to clear A from256
the brain. One of the principal routes is by the low257
density lipoprotein receptor-related protein (LRP),258
specifically LRP-1, a major cell surface A clear-259
ance receptor located on vascular smooth muscles cells260
that allows the transport of A peptides through the261
BBB [46] (Fig. 1D). LRP-1 is also found in neurons262
where it mediates A-induced oxidative stress and263
intraneuronal transport, causing mitochondrial dys-264
function [47, 48]. A is also cleared from the brain265
by A chaperones such as ApoE isoforms (ApoE2,266
ApoE3, or ApoE4), by microglia and perivascular267
brain macrophages, by direct enzymatic degradation268
of A in the brain, and by passive drainage of A into269
the perivascular space [46, 49]. The influx of periph-270
eral A to the brain is mediated by the receptor for271
advanced glycation end products (RAGE) (Fig. 1D).272
RAGE acts as a cell surface receptor that binds A273
in BBB, neurons, and microglia [50]. Because of274
its diverse localization, RAGE contributes to vari-275
ous aspects of AD pathology, including A-induced276
inflammatory response, oxidative stress, and intraneu-277
ronal mitochondrial dysfunction [50]. At later stages278
of AD progression, tau protein, a soluble microtubule-279
associated protein, becomes hyperphosphorylated and280
forms intracellular NFTs. In AD, NFTs compromise281
intracellular transport and the structural integrity of282
neurons [2, 51]. Hypoxia-induced alterations in AD283
metabolism may drive NFT formation (Fig. 1C). Both284
senile plaques and NFTs are used as markers for the285
definitive diagnosis of AD in postmortem brain.286
Hypoxia increases Aβ production through its287
effects on Aβ signaling pathways288
The bulk of experimental evidence linking hypoxia289
to AD pathology indicates that hypoxia exerts powerful290
modulatory effects on the A signaling pathway. Stud-291
ies of postmortem brain tissue have found that mild292
and severe ischemic episodes are associated with ele-293
vated levels of APP [52] and aggregation of A1-40294
and A1-42 [53]. Similar studies using immunohisto-295
chemical evaluations of axonal pathology have shown296
an increase in APP and A following severe head297
injury and cerebral ischemia [54–56]. Likewise, ani- 298
mal studies in vivo have demonstrated increased levels 299
of APP and A and upregulation of BACE1 under 300
hypoxic conditions [57, 58]. Significantly, only a sin- 301
gle, mild temporal occlusion (4 min) of the common 302
carotid arteries in adult (3 months) 3xTg-AD mice was 303
sufficient to produce acute elevations in A levels by 304
enhancing BACE1 that were sustained for at least 3 305
weeks [58]. Also, mild hypoperfusion produced a long- 306
lasting reduction in tau, presumably through autophagy 307
and ubiquitin-proteosomal pathway activation within 308
the affected brain region [58]. Hypoperfusion altered 309
phosphorylated tau proteins [58] that have been impli- 310
cated in the long-term formation of NFTs in AD 311
patients [58, 59]. In much older 3xTg-AD mice (15 312
months), a single but longer-lasting (12 min) occlu- 313
sion of the bilateral common carotid arteries did not 314
affect A levels, but rather enhanced APP phos- 315
phorylation and insoluble tau levels at three months 316
post-ischemia [60]. The same effects were produced in 317
wild-type controls, suggesting that these parameters of 318
global ischemia promote changes in AD-related path- 319
ways in this strain of aged mice regardless of genetic 320
profile [60]. Other studies with knock-out transgenic 321
mice confirm APP involvement in responses to vas- 322
cular insults [61]. Global cerebral ischemia, performed 323
by transient bilateral clamping of the common carotid 324
arteries in mice lacking either APP or BACE1 genes 325
(APP −/− and BACE −/−) increased the risk of 326
mortality and reduced CBF compared to wild-type lit- 327
termates [61]. Moreover, two molecules involved in 328
vascular regulation, serum response factor and calse- 329
questrin, were also significantly altered in both strains 330
[61]. Thus, studies with APP and BACE1 knockouts 331
suggest a beneficial role for APP and its cleavage 332
fragments in the regulation of blood flow and the 333
adaptation to ischemic insults. Taken together, results 334
with transgenic mice confirm APP involvement in the 335
brain’s response to hypoperfusion, whereas hypoxic 336
insults produce variable effects on A and tau levels. 337
Chronic hypoxia appears to produce more pro- 338
nounced and consistent effects on AD pathology. 339
In a recent study APP/PS1 transgenic mice were 340
exposed daily to hypoxia treatment for two months 341
that produced numerous deficits associated with 342
AD pathology, including worsened cognitive deficits, 343
increased A accumulation and subsequent forma- 344
tion of A plaques, and increased levels of tau 345
phosphorylation [62]. Similarly, long-term chronic 346
hypoxia treatment was shown to produce more and 347
larger A plaques in two strains of transgenic mice 348
(APPSwe + PS1A246E and APP23) [63]. Different 349
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parameters for generating chronic hypoxia (8% O2 for350
16 h/day) in APP23 mice produced similar modula-351
tory effects on A pathways, namely upregulation of352
BACE1 promoter activity and increases in both BACE1353
transcription and expression in vivo [64]. This is354
turn upregulated BACE1 cleavage of APP, increased355
A production, deposits, and plaque formation, and356
worsened cognitive deficits in transgenic mice. Sim-357
ilar effects on cognitive function were observed in358
young adult mice (2 months) overexpressing a mutant359
form of human APP (APPsw/ind-Tg mice). These360
mice exposed to chronic hypoperfusion via bilat-361
eral common carotid artery stenosis using microcoils362
exhibited greater cognitive deficits and hippocampal363
neuronal loss compared with controls [65]. Notably,364
insoluble A was reduced, whereas soluble A was365
increased, following six months of cerebral hypoper-366
fusion, resulting in a reduction of A deposition and367
plaque formation, suggesting that the cognitive impair-368
ment and neuronal loss associated with stenosis in this369
transgenic line may be a result of soluble A species.370
In sum, chronic hypoperfusion produces effects on AD371
neuropathology that are more consistent with those372
observed in clinical cases, namely increases in A373
plaques, tau phosphorylation, and cognitive impair-374
ments.375
While chronic hypoxia has been shown to pro-376
duce profound impairments in cognition and brain377
structure and function, hyperoxia treatment has been378
shown to have opposite effects. Chronic hyperoxia379
treatment (40% O2; 8 h/day for 4 or 8 weeks) in young380
adult APP/PS1 transgenic mice produced significant381
improvements in spatial learning and memory and382
decreased A deposition and plaque formation in cor-383
tex and hippocampus [66]. Biochemical analysis of384
brain tissue indicated that hyperoxia treatment reduced385
A by inhibiting -secretase activity. The results of386
this study support the application of oxygen therapy as387
a useful way to reduce the neuropathological changes388
associated with AD progression, although this possi-389
bility requires further study.390
Studies examining vascular profiles in AD trans-391
genic mice have found that targeted mutations in these392
models not only produce forms of AD neuropathology393
but also various cerebrovascular pathologies. Imaging394
studies using magnetic resonance angiography to evi-395
dence cerebral arterial hemodynamics have shown that396
adult APP23 mice present flow voids in the internal397
carotid arteries that were observed as late as 20 months398
of age in large arteries in the circle of Willis. Vessel399
elimination and vessel deformation were also observed400
at the site of the flow voids [67]. Imaging techniques401
have also uncovered the deposition of A peptides 402
in intracortical vessels and its association with cere- 403
bral amyloidosis. A recent study using non-invasive 404
high resolution contrast enhanced magnetic resonance 405
angiography (CE-MRA) in 4- and 24-month-old 406
arcA mice showed an age-dependent reduction in 407
the quantity of intracortical vessels in arcA mice 408
compared to littermate controls [68]. Specifically, the 409
number of functional intracortical microvessels was 410
reduced in 24-month-old arcAmice compared to wild 411
type controls, whereas no differences were found in 412
four-month-old mice. Moreover, an accumulation of 413
A and fibrinogen, which is associated with vessel 414
stenosis and a reduction in CBF [68], was found in 415
small and medium sized vessels but not in large arter- 416
ies in 24-month-old arcAmice. These results suggest 417
that APP23 and arcA mice may be suitable models 418
for examining links between AD neuropathology and 419
neurovascular disease. 420
One of the principal vessel disorders associated with 421
AD is cerebral amyloid angiopathy (CAA), which pro- 422
duces vascular deposits of A similar to the senile 423
plaques in AD (Fig. 1B). One outcome of CAA-related 424
capillary occlusion is disruption of CBF, which leads 425
to A toxicity [69]. Aged APP23 mice exhibit CAA- 426
related capillary occlusion in thalamic vessels that 427
is not evident in control transgenic APP51/16 or 428
wild type mice [70]. CAA has also been linked with 429
ApoE expression. APPsw mice expressing endoge- 430
nous murine ApoE or human ApoE3 and ApoE4 431
isoforms (knock-in mice Tg2576) develop amyloid 432
plaques as well as CAA [71]. APPsw mice express- 433
ing ApoE4 at 15 months of age showed a change in A 434
deposition that lead to substantial CAA compared to 435
age-matched mice expressing ApoE3 [71], providing 436
evidence that links ApoE expression with A retention 437
in the brain by interfering with A clearance mech- 438
anisms. Thus, AD transgenic mice provide evidence 439
that capillary occlusion, which is present in human AD 440
brains, is related also to CAA, pointing to these trans- 441
genic lines as useful models for gaining mechanistic 442
insights into neurovascular and AD pathologies. 443
Additional evidence supporting the association 444
between hypoxia and the development of A pathol- 445
ogy has been derived from studies with non-transgenic 446
animals (Table 2). For instance, rats that received bilat- 447
eral intracerebroventricular injections of A fragments 448
and permanent occlusion of bilateral common carotid 449
arteries showed greater impairments in spatial memory 450
and more extensive AD neuropathology relative to ani- 451
mals that received A toxicity or occlusion alone [72]. 452
Similarly, aged rats exposed to reversible occlusion of 453
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the cerebral middle artery that produced focal cere-454
bral ischemia showed an upregulation of APP and455
A fragments [73]. The presence of APP and A456
immunoreactivity in the infarct region indicated that457
concomitant reductions in CBF and cerebral ischemia458
provide the necessary elements for focal accumula-459
tion of APP and A in adult rats [73]. Importantly,460
studies show that the effects of hypoxia on AD pathol-461
ogy can persist in time. A mild microsphere embolism462
in aged rats promoted eNOS expression and protein463
tyrosine nitration in microvascular endothelial cells,464
leading to A accumulation in the lesioned area and465
hyperphosphorylation of tau protein in surrounding466
neurons [74, 75]. Both A accumulation and hyper-467
phosphorylated tau remained elevated for 12 weeks,468
indicating long-lasting effects of neurovascular injury469
on A neurodegeneration [74, 75].470
Chronic bilateral occlusion of the common carotid471
arteries in rats also reproduces several characteris-472
tics of human AD. Chronic hypoperfusion in adult473
rats has been shown to promote accumulation of474
oligomeric A and impaired learning and memory that475
progressed as the period of hypoperfusion increased476
[76]. Significantly, hypoperfusion caused the down-477
regulation of various proteins important for synaptic478
plasticity and cognitive function including growth-479
associated protein-43 (GAP-43), synaptophysin, and480
microtubule-associated protein-2 (MAP-2) [76]. Sim-481
ilar effects were observed following double ligation482
of the carotid arteries in adult rats, namely profound483
deficits in spatial memory in aged but not young484
rats after 30 days that worsened after 180 days [77].485
Hypoperfusion also caused an accumulation of A486
oligomers in the CA1 region 180 days after surgery487
and synaptic changes in CA1 that correlated with the488
structural changes observed in AD progression [77].489
Early studies demonstrated that permanent occlusion490
of bilateral common carotid arteries produced progres-491
sive neuronal damage in the hippocampus and white492
matter, evidenced by increased degeneration from one493
to four months after cerebral hypoperfusion [78].494
Also, hypoperfusion produced long-lasting decreases495
in acetylcholinergic levels in cortex, striatum, and hip-496
pocampus after four months. These results suggest497
that progressive structural and functional changes in498
hippocampus and other brain areas play a role in the499
cognitive decline that occurs in aged persons following500
chronic hypoperfusion [78]. Moreover, other studies501
have reported that the observed hypoperfusion-induced502
deficits in spatial learning are a product of altered503
energy metabolism in various brain areas in addition504
to the hippocampus that are responsible for visuo-505
motor integration [79]. On the other hand, there is 506
evidence that the nature of structural changes varies 507
post-ischemia. Global forebrain ischemia produced 508
by bilateral carotid occlusion resulted in a loss of 509
90% of CA1 neurons 24 to 72 hours after ischemia 510
and a decrease in APP and A at 24 hours follow- 511
ing ischemia in aged gerbils [80]. At 48 hours, there 512
was an increase in APP and A that overlapped 513
with increased ApoE that may provide circumstances 514
that are favorable for the formation of A oligomers 515
after ischemic insults [80]. Together, these results 516
demonstrate that ischemia produces profound and 517
long-lasting effects on brain tissue that are consistent 518
with AD neuropathology, but that the spatial-temporal 519
pattern of these effects varies among studies. 520
Evidence regarding hypoxia-ischemia effects on 521
Aβ clearance mechanisms 522
A is cleared from the brain through receptor- 523
mediated endocytosis by cells in the parenchyma or 524
through the BBB [81], but during a hypoxic episode 525
the A clearance mechanism is impaired. Systemic 526
inflammation is one of the causes of impaired efflux 527
of A from the brain [82]. Young adult mice treated 528
with lipopolysaccharides (LPS) showed several dis- 529
turbances including inhibition of CSF bulk flow, 530
impairment of central and peripheral clearance of A, 531
and increased vascular sequestration of A [82], which 532
together suggest that inflammatory responses disrupt 533
A transport and clearance that may exacerbate AD 534
pathology. Other A transport molecules that are capa- 535
ble of modulating cerebral blood flow responses and 536
AD pathological processes include LRP1 and RAGE. 537
Inhibition of RAGE, one of the receptors for A in 538
the BBB, has been shown to have positive effects on 539
CBF and AD pathology. In one study, RAGE inhi- 540
bition was shown to normalize CBF responses and 541
cognitive performance in aged APP mice [50]. In 542
mice that overexpress human APP (APPsw/0), a 543
high affinity RAGE specific blocker (FPS-ZM1) inhib- 544
ited -secretase activity and A production, reduced 545
A1-40 and A1-42 levels in the brain, and normalized 546
cognitive performance and CBF in aged animals [50]. 547
Modulation of LRP1 has also been shown to impact 548
AD pathology and vascular processes in the brain. 549
Evidence from studies with young and adult mice indi- 550
cates that LRP-1 decreases with age [83]. Hepatic 551
A uptake, which accounts for 40–60% of total A 552
uptake, is also attenuated in aged rats, suggesting that 553
A levels increase during the normal aging process 554
as a consequence of insufficient systemic clearance 555
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[84]. Some proteins like receptor-associated protein556
(RAP)-chaperone facilitate the trafficking of LRP-1 by557
binding to multiple sites on LRP-1 and competitively558
blocking all known LRP ligands [83, 85]. It has been559
reported that increasing RAP concentrations decreases560
A clearance [86]. Transgenic mice with decreased561
levels of LRP-1 exhibit greater A accumulation than562
wild-type mice [86]. The increased levels of A pro-563
mote proteasome-dependent degradation of LRP-1 that564
lead to increased A accumulation in a positive feed-565
back loop, suggesting that A peptides compete for566
the same LRP-mediated efflux system in order to exit567
the brain [86]. Animal experiments suggest that higher568
levels of A may completely saturate LRP-1 leading569
to vascular accumulation of A and subsequent devel-570
opment of cerebrovascular amyloid protein deposits571
[83]. As such, if the levels of extracellular A exceed572
the transport capacity of LRP-1 or the transport sys-573
tems are impaired by downregulation of LRP-1, A574
could accumulate in brain tissue and vessels [83, 86,575
87], producing toxicity and neuronal death.576
Evidence linking hypoxia-induced pathology and577
genetic risk factors for AD578
The ApoE4 polymorphism is a common risk fac-579
tor in AD and CAA, and recent studies have revealed580
potential mechanisms linking ApoE4 to both diseases.581
Studies of postmortem brain tissue have found that582
mild and severe ischemic episodes are associated with583
increases in ApoE in the hippocampus [53]. Likewise,584
transgenic mice (Tg2576) expressing human ApoE4585
showed substantial CAA and increased A40 : 42 ratios586
in brain [71]. A more recent study showed that ani-587
mals expressing human ApoE4 genes that received588
intracerebral injections of human A1-40 presented589
significantly greater A deposition in the hippocam-590
pus than those expressing ApoE3 at both 3 and 16591
months of age, suggesting that ApoE4 disrupts A592
clearance from the brain [88]. Further, the disruption in593
A clearance was linked to morphological changes in594
the vasculature of aged mice [88]. Taken together, these595
studies suggest an age-dependent effect of ApoE4596
expression on the elimination of A from the brain597
along vascular basement membranes. Similar links598
between ApoE expression and cerebrovascular pro-599
cesses have been found in studies with non-transgenic600
animals. Aged Wistar rats exposed to transient middle601
cerebral artery occlusion showed long-term changes in602
ApoE immunoreactivity and mRNA expression [89].603
After seven days of occlusion the maximal increase604
of ApoE expression was detected in the core, and605
at 21 days increased ApoE was detected in the peri- 606
ischemic region in glial cells but not in neurons. 607
Another source of ApoE expression was macrophages, 608
which was attributed to necrotic tissue clearance after 609
the ischemic insult. Together, studies with transgenic 610
and non-transgenic animals link ischemic episodes 611
with increased ApoE expression, which may disrupt 612
A clearance from the brain in a time-dependent man- 613
ner post-ischemia. 614
Recently identified genetic risk factors for late onset 615
AD can be present at low frequency but can represent 616
almost the same risk as the common sporadic genetic 617
risk factor ApoE. Some of these genetic variants such 618
as TREM2, complement receptor-1 (CR1), and CD33 619
participate in microglia activation and the subsequent 620
development of A protein deposits [90, 91]. Expres- 621
sion of CD33, a transmembrane protein that encodes 622
a myeloid cell-surface receptor, is a risk factor for AD 623
and has been shown to inhibit the uptake and clearance 624
of A42 in microglial cell cultures [92]. Further, studies 625
in transgenic mice show that TREM2 expression is pos- 626
itively correlated with amyloid phagocytosis whereas 627
TREM2 inhibition is related to accumulation of toxic 628
products in brain [93]. Lastly, the presence of the CR1 629
risk allele or CR1 AD risk variant gene is related 630
to impaired clearance and deposition of A in brain 631
and to an increased rate of cognitive decline [94–96]. 632
Although these three genetic variants (TREM2, CD33, 633
and CR1) occur less frequently than ApoE ε4 allele, 634
they represent sporadic genetic risk factors for AD sim- 635
ilar to ApoE ε4 and implicate microglial impairment as 636
a factor in promoting AD neuropathological processes. 637
Hypoxia and head injury-produced Aβ pathology 638
Clinical studies have shown that head injury gener- 639
ates ischemic changes that induce tau-like pathology 640
and APP cleavage [34, 97]. A plaques have been 641
seen in 30% of patients who die from traumatic brain 642
injury (TBI) [98]. The accumulation of A after TBI 643
is believed to result from axonal damage [99, 100], 644
which interrupts axonal transport and results in an 645
accumulation of proteins in the axon, including APP 646
[101, 102]. Several studies have used animal models to 647
examine the pathology of A accumulation following 648
TBI [98, 103–105]. In one study, hippocampal damage 649
and behavioral deficits were seen as a result of TBI 650
in 3xTg-AD mice [105]. There was also an increase 651
in A accumulation in pericontusional white matter 652
and an increase in total insoluble A. Notably, the 653
increase of A in white matter was dependent on the 654
severity of injury [105]. Similarly, a study conducted 655
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in a swine model found an increase in APP and co-656
accumulation of A in swollen axons and neuronal cell657
bodies, as well as formation of diffuse parenchymal658
A plaques in both grey and white matter [106]. Fur-659
ther, adult 3xT-AD mice exposed to experimental TBI660
showed rapid intra-axonal A accumulation in the area661
of the injury, increased tau immunoreactivity in brain662
regions following moderate injury, and no A accu-663
mulation in areas without injury [105]. Together, the664
results of these studies suggest that trauma creates a665
unique situation in which all of the necessary enzymes666
for A formation co-exist in axons. These results are667
consistent with those found in humans, where TBI pro-668
duced long-term progressive axonal degeneration and669
intra-axonal A accumulation that persisted for years670
following the initial trauma [54]. Evidence suggests671
that following hypoxia, eventual lysis and breakdown672
of damaged axons may be the underlying mechanism673
of A release into the parenchyma where it aggre-674
gates and causes plaque formation [54]. In related675
studies using mice that overexpress normal human676
APP or a mutant form of APP brain injury produced677
an increase in A in brain tissue but not an increase678
in plaque formation [103, 104]. In mice overexpress-679
ing mutant APP, the increases in A led also to an680
increase in hippocampal neuronal death and memory681
impairment [104]. Clearly, brain injury produces alter-682
ations in Apathways that promote pathologies similar683
to AD, although plaque formation is not reliably pro-684
duced in some models.685
CONCLUSION686
Diagnostic criteria for dementias make a distinction687
between the impairment resulting from AD and that688
resulting from cerebrovascular insults despite evidence689
of extensive overlap between the two [17]. AD and vas-690
cular pathologies share several risk factors, and clinical691
and experimental research suggests that the burden of692
vascular and AD neuropathology may not be inde-693
pendent. The present review presented evidence from694
transgenic and non-transgenic rodent models linking695
AD and cerebrovascular neuropathology. Collectively,696
experimental studies with rodents provide strong evi-697
dence in favor of hypoxia-induced alterations in A698
metabolism that may in turn drive the neurotoxicity699
marked by NFT formation and subsequent cell death.700
First, studies with transgenic mice confirm that oxy-701
gen deficiency facilitates AD pathogenesis by altering702
APP expression and driving A overproduction [57,703
58, 60–65]. Importantly, chronic hypoperfusion pro-704
duces pronounced effects on AD neuropathology that 705
include increases in A plaques [63, 64] and tau hyper- 706
phosphorylation [62] and worsened cognitive deficits 707
[64, 65], which are not consistently observed following 708
mild hypoperfusion. Second, various AD transgenic 709
manipulations produce vascular pathologies that pro- 710
vide compelling evidence of links between molecular 711
pathways common to both AD and neurovascular dis- 712
ease [67, 68, 70, 71]. Third, studies with non-transgenic 713
animals indicate that hypoperfusion produces pro- 714
nounced effects on cognition, A accumulation and tau 715
hyperphosphorylation [72–78]. Fourth, various stud- 716
ies point to ischemia-induced time-dependent changes 717
in brain structure and function [77–80] particularly in 718
hippocampal areas afflicted in AD progression. Lastly, 719
various studies suggest that hypoxia effects on A 720
accumulation may reflect disruptions in A clearance 721
mechanisms [50, 71, 88]. Taken together, hypoxia- 722
induced effects may cause a significant shift toward 723
increased A deposition and reduced A clearance 724
that leads to the neurotoxic cascade and functional 725
deterioration characteristic of AD neuropathology. 726
The evidence reviewed favors links between 727
hypoxic insults and AD neuropathology, but variable 728
findings among studies limits the degree to which 729
rodent models can reliably reproduce human disease. 730
Rodent species are amenable to genetic manipulations 731
and large-scale studies, but differences between the 732
human and rodent brain and limitations in rodents’ 733
behavioral repertoire represent challenges to trans- 734
lation. For instance, the evidence reviewed suggests 735
that hypoxia-induced effects on A pathology are 736
more consistent across studies than effects on tau 737
pathology, ApoE, or cognitive impairment. Accord- 738
ingly, recent reviews have highlighted the limitations 739
of animal models to produce effective neuroprotec- 740
tive agents for ischemic stroke in clinical trials and 741
suggested that nonhuman primate models made be 742
a more appropriate albeit ethically more challenging 743
approach [107, 108]. Many biomarker-based studies 744
have established that the neuropathology associated 745
with AD, namely A deposits and NFTs, progressively 746
accumulates in the brain decades before behavioral 747
symptoms appear [2]. Therefore, it remains a viable 748
strategy to target the various vascular risk factors for 749
AD during pre-symptomatic stages in AD develop- 750
ment. In this regard, the use of rodent models continues 751
to be the more cost-effective approach to explore the 752
mechanistic factors linking reductions in CBF to AD- 753
related neuropathologies and behavioral deficits, and 754
the continued standardization and refinement of these 755
approaches should be pursued.
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